LEADER 02882nam  2200817z- 450 
001 9910557114503321
005 20231214133626.0
035   $a(CKB)5400000000040901
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69079
035   $a(EXLCZ)995400000000040901
100   $a20202105d2020      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aOutcomes and Therapeutic Management of Bladder Cancer
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 electronic resource (120 p.)
311   $a3-03936-934-2 
311   $a3-03936-935-0 
330   $aBladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
606   $aMedicine$2bicssc
610   $abladder cancer
610   $arobotic-assisted
610   $aopen
610   $aradical cystectomy
610   $asurvival
610   $apropensity score
610   $aage
610   $aurothelial carcinoma
610   $aoutcome
610   $aanesthesia recovery periods
610   $acognitive impairment
610   $agamma-cyclodextrins
610   $aneuromuscular blockade
610   $arobotic radical cystectomy
610   $aglycogen
610   $aclear-cell adenocarcinoma
610   $aurinary bladder
610   $aSEER program database
610   $afemale
610   $aintracorporeal neobladder
610   $aoutcomes
610   $arobotic
610   $asex-sparing
610   $amethylation
610   $abiomarkers
610   $aFOXA1
610   $aGATA3
610   $aKRT20
610   $amolecular markers
610   $amRNA
610   $amuscle-invasive bladder cancer
610   $aPCR
610   $ahuman epidermal growth factor receptor 2
610   $aindoleamine 2,3-dioxygenase
610   $aprogrammed death ligand-1
610   $aimmunotherapy
610   $anodal disease
610   $apN1
610   $aneoadjuvant
610   $aadjuvant
610   $achemotherapy
615  7$aMedicine
700   $aMoschini$b Marco$4edt$0481847
702   $aMoschini$b Marco$4oth
906   $aBOOK
912   $a9910557114503321
996   $aOutcomes and Therapeutic Management of Bladder Cancer$93038144
997   $aUNINA